Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

By M. Christ-Crain, D. Stolz, R. Bingisser, C. Müller, D. Miedinger, P. Huber, W. Zimmerli, S. Harbarth, M. Tamm, B. Müller. American Journal of Respiratory and Critical Care Medicine, 2006

884 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/a41647ba5d1688ef88a414ad526ff105cfadbafd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Graf
2. J. Metlay
3. P. Rohner
4. J. Pugin
5. A. Anzueto
6. G. Waterer
7. S. Harbarth
8. Ann C. Long

Citations in the corpus

• Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America (2019, background): “Some patients with low procalcitonin levels have CAP and have been safely treated without antibiotics (7), but these represent small subgroups, raising concerns about the safety of widely using such a strategy.”
• Guidelines for the management of adult lower respiratory tract infections - Full version (2011, unknown): “[417] Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial RCT 2B+”
• Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. (2009, unknown): “4 (8 [4-12]) 9.”
• Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. (2008, methodology): “Overall, it was shown that PCT guidance allows reducing the use of antibiotics in patients presenting with symptoms of lower respiratory tract infection (9), in patients with acute exacerbation of chronic bronchitis (28), and in patients with community-acquired pneumonia (10).”